文献速递免疫规划慢病防控与筛查卫生政策与健康促进

一项大型人群前瞻性队列研究中COVID-19疫苗接种诱导的抗体应答及按年龄和合并症状态的分化

COVID-19 vaccination-induced antibody responses and waning by age and comorbidity status in a large population-based prospective cohort study.
PubMed 文献 · Vaccine · 2024-07-14

在荷兰成年人前瞻性队列中每六个月采集血清,计算基础系列、第一剂和第二剂加强接种后针对SARS-CoV-2刺突蛋白受体结合域抗体的几何平均浓度(GMC)。纳入基础系列、第一剂和第二剂加强后样本分别为20,640、15,229和8,392份。随接种剂次增加,年龄和医疗风险组间抗体差异变小,作者认为额外接种优先排序应参考COVID-19疾病严重程度而非抗体水平。

要点

  • 基础系列后2-6周和21-25周,高龄或医疗风险条件者GMC较低。
  • 第一剂加强后,高龄与2-6周和21-25周较低GMC相关。
  • 第一剂和第二剂加强后抗体衰减与年龄或医疗风险条件无关。

核心结论

  • 随接种剂次增加,年龄和医疗风险组间抗体差异变小,作者认为额外接种优先排序应参考COVID-19疾病严重程度而非抗体水平。

研究设计与样本

  • 荷兰成年人前瞻性队列研究,每六个月采集血清样本。
  • 纳入基础系列、第一剂加强和第二剂加强后样本分别为20,640、15,229和8,392份。
  • 采用线性回归估计年龄(18-59岁 vs 60-85岁)和医疗风险条件对GMC及抗体衰减的影响。

主要发现

  • 基础系列后2-6周和21-25周,高龄或医疗风险条件者GMC较低。
  • 第一剂加强后,高龄与2-6周和21-25周较低GMC相关。
  • 第一剂和第二剂加强后(仅60-85岁)抗体衰减与年龄或医疗风险条件无关。

关键数值与推荐

  • 基础系列后2-6周和21-25周,高龄或医疗风险条件者GMC较低。
  • 第一剂加强后2-6周和21-25周,高龄与较低GMC相关。
  • 第一剂和第二剂加强后3-25周抗体衰减与年龄或医疗风险条件无关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Information on the magnitude and duration of antibody levels after COVID-19 vaccination in different groups may be useful for prioritizing of additional vaccinations. METHODS: Serum samples were collected every six months in a prospective cohort study among adults in the Netherlands. Geometric mean concentrations (GMCs) of antibodies against the receptor binding domain of the SARS-CoV-2 spike protein were calculated after the primary series, first, and second booster vaccinations. Effects of age (18-59 vs 60-85 years) and medical risk conditions on GMC 2-6 weeks and 21-25 weeks after each vaccination, and on waning during 3-25 weeks after each vaccination, were estimated by linear regression. RESULTS: We included 20,640, 15,229 and 8,392 samples collected after primary, first and second booster vaccination, respectively. GMCs at 2-6 and 21-25 weeks after primary series were lower in participants with older age or medical risk conditions. After the first booster, older age was associated with lower GMC at 2-6 weeks and at 21-25 weeks. Waning after the first and second boosters (only 60-85) was not associated with age or medical risk conditions. CONCLUSIONS: Since antibody differences by age and medical risk groups have become small with increasing number of doses, other factors such as COVID-19 disease severity rather than antibody levels are useful for prioritization of additional vaccinations.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Hoeve CE, Huiberts AJ, de Gier B, et al. COVID-19 vaccination-induced antibody responses and waning by age and comorbidity status in a large population-based prospective cohort study. Vaccine. 2024. PMID: 38997851. doi:10.1016/j.vaccine.2024.07.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。